Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

68Ga PentixaFor - PentixaPharm

Next Previous
Drug Profile

68Ga PentixaFor - PentixaPharm

Alternative Names: 68Ga PentixaF; 68Ga-PTF; 68Ga-PentixaFor; [68Ga]Ga-PentixaFor; [68Ga]Ga-PentixaFor PET/CT; [68Ga]Ga-PTF; [68Ga]Pentixafor; CXCR4-PET; PT 001 - PentixaPharm; PT-001 - Pentixapharm

Latest Information Update: 28 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Scintomics; University of Munich
  • Developer Institut de Cancerologie de l'Ouest; Peking Union Medical College Hospital; PentixaPharm
  • Class Antineoplastics; Cyclic peptides; Diagnostic agents; Gallium radioisotopes; Imaging agents; Radiopharmaceutical diagnostics
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Marginal zone B-cell lymphoma
  • Phase II/III Adrenal cancer
  • Phase II Hyperaldosteronism; Lymphoma; Multiple myeloma; Myocarditis
  • Phase I/II Cushing syndrome
  • Phase 0 Triple negative breast cancer
  • No development reported Blood dyscrasias; Giant cell arteritis; Lymphoproliferative disorders; Myocardial infarction; Neuroendocrine tumours; Non-Hodgkin's lymphoma; Smoldering multiple myeloma; Thymoma

Most Recent Events

  • 28 Jul 2026 No recent reports of development identified for phase-0 development in Thymoma(Diagnosis) in China (IV, Injection)
  • 29 Jun 2026 PentixaPharm completes a phase II trial in Hyperaldosteronism (Diagnosis) in France (IV) (CTIS2023-505507-22-00)
  • 09 Jun 2026 Pentixapharm Holding received positive feedback and clearance from the FDA for IND for the initiation of the phase III PANDA study in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top